Leerink Partners maintains Twist Bioscience at Outperform, lowers price target to $175 from $190

What happened

Leerink Partners kept its Outperform rating on Twist Bioscience but cut its price target to $175 from $190. The new target is 7.9% lower than the previous one and implies 53.2% upside from the November 12 closing price of $114.22.

Confirmed

Global impact / market context

The lower target signals that Leerink sees less potential value than before, even while retaining a positive rating. If investors use analyst targets to guide their decisions, the cut could temper expectations for Twist’s shares, though the article does not report any resulting price move.

Analyst inference

The article’s comparison targets range from $135 to $150, below Leerink’s $175 target. This shows Leerink’s stated valuation is higher than those recent analyst comparisons, but the article gives no company results or explanation for why analysts differ.

Analyst inference

What to watch

1. Watch for later analyst updates that maintain or revise their ratings and targets; further cuts could weaken expectations, while increases could reinforce confidence in Twist’s shares. Analyst inference
2. Compare any future targets with the listed recent range of $135 to $150, while recognizing that analyst targets are estimates, not promised trading prices. Analyst inference
3. The article gives no explanation for Leerink’s target reduction, so future company or analyst disclosures may clarify what drove the lower estimate. Analyst inference

Evidence

• Original source link unavailable